check_circleStudy Completed

Contraception

Bioavailibility/Bioequivalence of Yaz/Nardis (Russia)

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

55 - 75 Years
  • -

  • -

Trial summary

Enrollment Goal
26
Trial Dates
March 2010 - May 2010
Phase
Phase 1
Could I Receive a placebo
N/A
Products
EE/DRSP (Yasmin Product Family)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Completed
SocraTec R&D Clinical WardErfurt, 99084, Germany

Trial design

Characterization of relative bioavailability and assessment of bioequivalence of Nardis (Test) in comparison to Yaz (Reference) both containing 3 mg drospirenone and 0.02 mg ethinylestradiol in a single dose, two way crossover, open, randomized study under fasting conditions in postmenopausal women
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A